These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Simultaneous removal of T and B cell epitope in recombinant staphylokinase by structure-based mutagenesis of immuno-dominant Arg77 and Glu80 residues. Xu R; He J; Jia K; Chen X; Liu J; Zhu K Wei Sheng Wu Xue Bao; 2011 May; 51(5):692-703. PubMed ID: 21800633 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic and thrombolytic properties of cysteine-linked polyethylene glycol derivatives of staphylokinase. Vanwetswinkel S; Plaisance S; Zhi-Yong Z; Vanlinthout I; Brepoels K; Lasters I; Collen D; Jespers L Blood; 2000 Feb; 95(3):936-42. PubMed ID: 10648406 [TBL] [Abstract][Full Text] [Related]
10. Simultaneous elimination of T- and B-cell epitope by structure-based mutagenesis of single Glu80 residue within recombinant staphylokinase. He J; Xu R; Chen X; Jia K; Zhou X; Zhu K Acta Biochim Biophys Sin (Shanghai); 2010 Mar; 42(3):209-15. PubMed ID: 20213046 [TBL] [Abstract][Full Text] [Related]
11. Comparative immunogenicity and thrombolytic properties toward arterial and venous thrombi of streptokinase and recombinant staphylokinase in baboons. Collen D; De Cock F; Stassen JM Circulation; 1993 Mar; 87(3):996-1006. PubMed ID: 8443918 [TBL] [Abstract][Full Text] [Related]
12. Elimination of a human T-cell region in staphylokinase by T-cell screening and computer modeling. Warmerdam PA; Plaisance S; Vanderlick K; Vandervoort P; Brepoels K; Collen D; De Maeyer M Thromb Haemost; 2002 Apr; 87(4):666-73. PubMed ID: 12008950 [TBL] [Abstract][Full Text] [Related]
13. Construction of a novel Staphylokinase (SAK) mutant with low immunogenicity and its evaluation in rhesus monkey. Wang M; Chen Y; Fu W; Zou M; Wang Y; Xing W; Wang J; Xu D Int J Biol Macromol; 2020 Mar; 146():781-789. PubMed ID: 31730959 [TBL] [Abstract][Full Text] [Related]
14. Structure-function relationships in staphylokinase as revealed by "clustered charge to alanine" mutagenesis. Silence K; Hartmann M; Gührs KH; Gase A; Schlott B; Collen D; Lijnen HR J Biol Chem; 1995 Nov; 270(45):27192-8. PubMed ID: 7592976 [TBL] [Abstract][Full Text] [Related]
16. Randomized coronary patency trial of double-bolus recombinant staphylokinase versus front-loaded alteplase in acute myocardial infarction. Vanderschueren S; Dens J; Kerdsinchai P; Desmet W; Vrolix M; De Man F; Van den Heuvel P; Hermans L; Collen D; Van de Werf F Am Heart J; 1997 Aug; 134(2 Pt 1):213-9. PubMed ID: 9313600 [TBL] [Abstract][Full Text] [Related]
17. Construction and characterization of novel staphylokinase variants with antiplatelet aggregation activity and reduced immunogenecity. Su HB; Zhang YG; He JT; Mo W; Zhang YL; Tao XM; Song HY Acta Biochim Biophys Sin (Shanghai); 2004 May; 36(5):336-42. PubMed ID: 15156275 [TBL] [Abstract][Full Text] [Related]
18. Differential inhibition with antifibrinolytic agents of staphylokinase and streptokinase induced clot lysis. Lijnen HR; Stassen JM; Collen D Thromb Haemost; 1995 May; 73(5):845-9. PubMed ID: 7482414 [TBL] [Abstract][Full Text] [Related]
19. Fibrin-selective thrombolytic therapy with recombinant staphylokinase. Collen D; Vanderschueren S; Van de Werf F Haemostasis; 1996 Oct; 26 Suppl 4():294-300. PubMed ID: 8979135 [No Abstract] [Full Text] [Related]
20. Characterization of the interaction between plasminogen and staphylokinase. Lijnen HR; De Cock F; Van Hoef B; Schlott B; Collen D Eur J Biochem; 1994 Aug; 224(1):143-9. PubMed ID: 8076635 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]